CATALYSTYahoo • 2d ago
DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins RiseDXCM shares rise as Q3 earnings and revenues beat estimates, margins expand and 2026 guidance improves, driven by strong U.S. demand and G7 15 Day adoption.
Why OPK Stock surged +2.47% Today — RQD Quant Desk Flash
$1.66 +2.47% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.66
OPKO Health Inc. (OPK) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $1.24B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on OPK Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is OPK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, OPKO Health Inc. (NASDAQ: OPK) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.66 (+2.47% 1D, market cap $1.24B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OPK ranks #663 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does OPK compare to SLN and SNDX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OPK carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of 33.9%, and ROIC of -10.2%. By comparison, SLN (Silence Therapeutics Plc American Depository Share) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $1.23B) and SNDX (Syndax Pharmaceuticals Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $1.26B). Among the 5-stock peer group, OPK leads on earnings multiple (N/A) while LBRX leads on capital efficiency (-8.4% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for OPK?
▼
Per OPK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000944809), OPKO Health Inc. generated $606.9M in revenue (-14.9% YoY), -$225.68B in net income, and -$178.5M in free cash flow against $1.93B in total assets and $2.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.66 (+0.25%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (39/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-8.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OPK)Realized 20D OHLCV Swing Band: ±11.7%
Deterministic 5-Pillar Attribution (39/100 Composite)
🔍 WHY OPK SCORES 39/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+12/20 pts (31% of score)
FRED Regime × Technicals: 86% of 52W Range • RSI-14 at 58.9 (BULLISH MOMENTUM)
▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (28% of score)
20D Institutional Volume Accumulation (±11.7% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.38+10.9% Next Q
31
Q2 (-2Q)Grade E$1.53+6.5% Next Q
34
Q3 (-1Q)Grade E$1.63+1.8% Next Q
36
CurrentGrade D-$1.66-7.6% Hist 90D α
39
Trajectory: E (31) → D- (39)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a OPK Turnaround Squeeze
While OPK currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.56) and Max Pain ($1.74) forces dealer call-delta covering toward $1.86.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $OPK• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OPK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why OPK Stock surged +2.47% Today — RQD Quant Desk Flash
OPKO Health Inc. (OPK) surged +2.47% to $1.66, trading at 86% of its 52-week range ($0.98 – $1.77). Stretched risk/reward at current multiples (-10% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 86% of its 52-week range ($0.98 – $1.77) with RSI-14 at 58.9 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.7% around $1.66 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 33.9% gross margin and $0 annual free cash flow.
Live OPK Headlines & Catalysts
CATALYSTYahoo • 2d ago
DaVita Q3 Earnings Beat Estimates on IKC Strength, Revenues Rise Y/YDVA's Q3 earnings surge 52.2% as revenues rise 4.6%, fueled by strong kidney care and international growth despite rising costs and margin pressure.
CATALYSTYahoo • 3d ago
Reasons to Hold Hinge Health Stock in Your Portfolio for NowHNGE's strong revenue growth, raised 2026 outlook and expansion into Migraine and GI care support its growth prospects despite investment pressures.
CATALYSTYahoo • 3d ago
Baxter Q3 Earnings Beat on Broad-Based Growth, '26 Outlook RaisedBAX beats Q3 earnings and revenue estimates, driven by broad-based segment growth, and raises its 2026 outlook despite continued margin pressure.
CATALYSTYahoo • 4d ago
GEHC Q3 Earnings Beat Estimates on Strong Growth, '26 View RaisedGE HealthCare's Q3 earnings and revenues beat estimates on strong segment growth and higher margins, driving raised 2026 guidance as shares gain 8.3%.
MARKET WIREYahoo • 4d ago
OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a multinational biopharmaceutical company, today announced that it will report operating and financial results for the third quarter 2026 o
CATALYSTYahoo • 4d ago
Cencora to Acquire AON in $2.4B Deal to Expand Oncology NetworkCOR's $2.4B acquisition of AON aims to expand its oncology services platform, strengthen community cancer care and support long-term growth.
CATALYSTYahoo • 5d ago
Ecolab Q3 Earnings In-Line With Estimates, Revenues Increase Y/YECL's Q3 earnings increase 5% to $2.18 per share, while revenues jump 13%, driven by strong Water and Life Sciences growth and accelerating digital sales.
CATALYSTYahoo • 5d ago
Here's Why You Should Hold PacBio Stock in Your Portfolio for NowPACB's growing clinical adoption, advanced sequencing technologies and rising consumables sales support growth, but funding headwinds and margin pressures persist.
MARKET WIREYahoo • 5d ago
Waters & Labcorp Expand Access to FDA-Approved HPV Screening TestsWAT partners with Labcorp to expand access to FDA-approved HPV testing by late 2026, potentially boosting diagnostics adoption and cervical cancer screening.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OPK)
- ✓Walkthrough of OPK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
OPK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +46.90%▲ ASCENDING CHANNEL
2026-10-30O $1.66H $1.69L $1.64C $1.66VOL 2.15M
RES: $1.78SUP: $1.33SMA50: $1.56SMA200: $1.34
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
OPK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -14.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on OPK today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for OPK. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OPK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OPK)
Health Care Rank #663 of 1016
⚔️ SLN vs OPK Full Matrix →
1. Head-to-Head Health Care Peer Comparison (OPK vs. SLN, SNDX, LBRX, VSTM)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, OPKO Health Inc. (OPK) ranks #663 by composite RQD confidence (39/100, grade D-) and #333 by equity capitalization ($1.24B). Within this direct 5-issuer industry benchmark cohort, OPK leads on earnings valuation at N/A trailing P/E, while LBRX leads on capital efficiency and profitability with -8.4% ROIC and — gross margin. LBRX currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with OPK at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OPK
ACTIVE
OPKO Health Inc. | D- | 39/100 | — | 33.9% | -10.2% | +2.47% | $1.24B | Benchmark Subject |
| SLN Silence Therapeutics Plc American Depository Share | E | 34/100 | — | 61.5% | -35.0% | +0.46% | $1.23B | /sln-vs-opk → |
| SNDX Syndax Pharmaceuticals Inc. | E | 31/100 | — | — | -35.0% | -1.19% | $1.26B | /sndx-vs-opk → |
| LBRX LB Pharmaceuticals Inc | D- | 43/100 | — | — | -8.4% | +0.80% | $1.30B | /lbrx-vs-opk → |
| VSTM Verastem Inc. | E | 24/100 | — | — | -35.0% | -1.78% | $1.17B | /vstm-vs-opk → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000944809In its most recent audited fiscal period (FY2025, filed 2025-12-31), OPKO Health Inc. (OPK) reported GAAP revenue of $606.9M (-14.9% vs. FY2024 revenue of $713.1M , and -29.7% cumulative change since FY2023) , GAAP net income of -$225.68B, operating cash flow of -$178.5M, and free cash flow of -$178.5M (+2.7% YoY). On the balance sheet, OPK closed FY2025 with $1.93B in total assets against $2.3M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $606.9M | -$225.68B | -$178.5M | -$178.5M | $1.93B | $2.3M |
| FY2024 (FY) | 2024-12-31 | $713.1M | -$53.22B | -$183.5M | -$183.5M | $2.20B | $3.0M |
| FY2023 (FY) | 2023-12-31 | $863.5M | -$188.86B | -$28.2M | -$28.2M | — | — |
3. OPK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs OPK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, OPKO Health Inc. (NASDAQ: OPK) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.66 (+2.47% 1D, market cap $1.24B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, OPK ranks #663 in composite RQD confidence.
How does OPK compare to SLN and SNDX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OPK carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of 33.9%, and ROIC of -10.2%. By comparison, SLN (Silence Therapeutics Plc American Depository Share) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $1.23B) and SNDX (Syndax Pharmaceuticals Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $1.26B). Among the 5-stock peer group, OPK leads on earnings multiple (N/A) while LBRX leads on capital efficiency (-8.4% ROIC).
What are the biggest fundamental strengths and SEC risk factors for OPK?
Per OPK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000944809), OPKO Health Inc. generated $606.9M in revenue (-14.9% YoY), -$225.68B in net income, and -$178.5M in free cash flow against $1.93B in total assets and $2.3M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is OPK trading relative to its 50-day, 200-day, and 52-week technical levels?
OPK last traded at $1.66 (+2.47% on volume of 1,976,749 shares), positioning the stock +6.41% above its 50-day simple moving average ($1.56) and +23.88% above its 200-day simple moving average ($1.34). Across its 52-week range of $0.98 to $1.77, OPK sits at the 86.1% percentile with a 14-day RSI of 58.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.7% ($1.47 to $1.85).
OPK Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is OPK stock moving today?
Why OPK Stock surged +2.47% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-10% return on capital) under elevated 10-year interest-rate pressure.